Patient Experience Is Key Element For Oncology Dose Optimization
The push for dose optimization in oncology should incorporate patient experience data, a Friends of Cancer Research White Paper recommends. ‘Tolerability’ is a key element to define in early development, and patient-reported outcomes can help.
You may also be interested in...
Avance Clinical’s CEO talks to Scrip about green shoots in US biotech funding, potential partnering in the AI space, the Australia rapid-start draw for early phase trials and the transition in the study design landscape in oncology for first-in-human trials.
Academic oncology centers and commercial sponsors should work together to ensure that studies begun without ‘registrational intent’ can nevertheless work for US FDA’s needs if circumstances change, a multi-stakeholder white paper urges.
The current crop of cancer drug approvals were well along in development when Project Optimus launched, meaning they may not have been able to implement the Oncology Center of Excellence’s premarket dose optimization policy.